These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33141503)

  • 21. Hepatitis C virus prevalence, determinants, and cascade of care among people who inject drugs in Iran.
    Khezri M; Mirzazadeh A; Shokoohi M; Sharafi H; Ghalekhani N; Tavakoli F; Mehmandoost S; Mousavian G; Imani M; Kakavand-Ghalehnoei R; Komasi A; Gouya MM; Haghdoost AA; McFarland W; Karamouzian M; Sharifi H
    Drug Alcohol Depend; 2023 Feb; 243():109751. PubMed ID: 36621200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use.
    Des Jarlais DC; Arasteh K; Feelemyer J; McKnight C; Barnes DM; Perlman DC; Uuskula A; Cooper HLF; Tross S
    Drug Alcohol Depend; 2018 Nov; 192():74-79. PubMed ID: 30243142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California.
    Horyniak D; Wagner KD; Armenta RF; Cuevas-Mota J; Hendrickson E; Garfein RS
    Int J Drug Policy; 2017 Sep; 47():9-17. PubMed ID: 28683432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Injection risk norms and practices among migrant Puerto Rican people who inject drugs in New York City: The limits of acculturation theory.
    Gelpí-Acosta C; Guarino H; Benoit E; Deren S; Pouget ER; Rodríguez A
    Int J Drug Policy; 2019 Jul; 69():60-69. PubMed ID: 31196730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
    Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC
    Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seroprevalence and risk factors associated with hepatitis C: a cross-sectional study of persons who inject drugs in Puerto Rico, 2018.
    Colón-López V; Alvelo-Fernández PM; Centeno-Alvarado N; Agudelo Salas IY; Rolón Colón Y; Pabón Martínez M; Rodríguez-Lebrón JL; Reyes-Pulliza JC
    BMC Public Health; 2023 Apr; 23(1):704. PubMed ID: 37072733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine.
    Iakunchykova O; Meteliuk A; Zelenev A; Mazhnaya A; Tracy M; Altice FL
    Int J Drug Policy; 2018 Jul; 57():11-17. PubMed ID: 29655101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013.
    Jordan AE; Des Jarlais DC; Arasteh K; McKnight C; Nash D; Perlman DC
    Drug Alcohol Depend; 2015 Jul; 152():194-200. PubMed ID: 25891230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.
    Handanagic S; Bozicevic I; Civljak M; Dominkovic Z; Sevic S; Barbaric J; Nemeth Blazic T; Dakovic Rode O; Begovac J
    Int J Drug Policy; 2016 Jun; 32():57-63. PubMed ID: 27160504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk behaviours and viral infections among drug injecting migrants from the former Soviet Union in Germany: Results from the DRUCK-study.
    Derks L; Gassowski M; Nielsen S; An der Heiden M; Bannert N; Bock CT; Bremer V; Kücherer C; Ross S; Wenz B; Marcus U; Zimmermann R;
    Int J Drug Policy; 2018 Sep; 59():54-62. PubMed ID: 30005420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
    Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cross-sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non-rural communities.
    Barranco MA; Rosenberg ES; Flanigan C; Shufelt S; Bruce EM; Wilberschied LA; Parker MM; Duncan E; Udo T
    J Viral Hepat; 2022 Nov; 29(11):994-1003. PubMed ID: 35925950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities.
    Heimer R; Eritsyan K; Barbour R; Levina OS
    BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S12. PubMed ID: 25253447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of HIV and other infections and injection behaviours among people who inject drugs in Addis Ababa, Ethiopia.
    Demissie M; Johnston LG; Muleta M; Desyebelew D; Belete W; G/Egxiabehre A; Gezahegn N; Kassa D; Aseffa Y
    Afr J AIDS Res; 2018 Sep; 17(3):259-264. PubMed ID: 30319040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing.
    Enkelmann J; Gassowski M; Nielsen S; Wenz B; Roß S; Marcus U; Bremer V; Zimmermann R;
    Harm Reduct J; 2020 Jan; 17(1):7. PubMed ID: 31924208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention.
    Eckhardt B; Winkelstein ER; Shu MA; Carden MR; McKnight C; Des Jarlais DC; Glesby MJ; Marks K; Edlin BR
    PLoS One; 2017; 12(5):e0177341. PubMed ID: 28542351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Situational assessment and epidemiology of HIV, HBV and HCV among people who use and inject drugs in Ghana.
    Guure C; Dery S; Baptista da Silva C; Asamoah-Adu C; Ayisi-Addo S; Diaba K; Loglo MG; Mohammed A; Sarpong YA; Hanu S; Torpey K
    PLoS One; 2024; 19(8):e0305923. PubMed ID: 39186757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015.
    Graham S; Maher L; Wand H; Doyle M; Iversen J
    Int J Drug Policy; 2017 Sep; 47():69-76. PubMed ID: 28735774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya.
    Sambai BC; Kingston H; Monroe-Wise A; Mbogo L; Juma E; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Scott J; Bosire R; Dunbar M; Macharia P; Masyuko S; Sinkele W; Herbeck JT; Farquhar C
    BMC Infect Dis; 2022 Jan; 22(1):73. PubMed ID: 35062890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of HIV, viral hepatitis B/C and tuberculosis and treatment outcomes among people who use drugs: Results from the implementation of the first drop-in-center in Mozambique.
    Semá Baltazar C; Kellogg TA; Boothe M; Loarec A; de Abreu E; Condula M; Fazito E; Raymond HF; Temmerman M; Luchters S
    Int J Drug Policy; 2021 Apr; 90():103095. PubMed ID: 33429163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.